Associated Papers
Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN et al.
Leukemia, 2017
Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
Kilbey A et al.
Journal of Cellular Biochemistry, 2017
A role for RUNX1 in hematopoiesis and myeloid leukemia.
Ichikawa M et al.
International Journal of Hematology, 2013
Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F.
Warshawsky I et al.
Blood, 2010
Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation.
Dowdy CR et al.
Human Molecular Genetics, 2010
Core binding factor at the crossroads: determining the fate of the HSC.
Link KA et al.
Journal of Cellular Physiology, 2010
RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.
Wolyniec K et al.
Oncogene, 2009
Select a paper to view details